In Conversation with Fredun Medhora, Managing Director and CFO, Fredun Pharmaceuticals Ltd.

In Conversation with Fredun Medhora, Managing Director and CFO, Fredun Pharmaceuticals Ltd.

"We have products which are innovative"

What is the mission and vision of Fredun Pharmaceuticals?

We wish to be a system-driven company which provides healthcare to all demographics. The vision is to be the largest holistic healthcare support system for any individual in India and across the countries that we export to.

What are your key growth levers?

We have the capacity to manufacture huge volumes of a variety of products which is very difficult for most other manufacturers. We have products which are innovative and also which are age old volume builders, all under one roof. A strong team with a focus on familiarisation and development is the key to our growth. 

What is your product mix strategy? Can you throw some light on revenue share product-wise?

We have various therapeutic classes and 50:50 export versus local. However, our local sales are also deemed exports via strategic partnerships with strong players for specific countries. We shall focus on sales in India from the next fiscal year. We hope to have 25 per cent of our annual sales coming from India alone in FY23.

What are your top three strategic priorities?

Currently, our top three strategic priorities are:

 Strategic partnerships with key players in various industries we are planning to enter.

 System-oriented operations.

 Conversion from B2B to B2C.

What is your outlook on the Indian pharmaceutical industry?

There will be severe consolidation in the next few years. There are a lot of players but a few good ones. The good ones will grow substantially higher than the ones who are not. The Indian market will also be more developed in the coming years to allow sophisticated players to operate and legalities will remove undue competition. We are at an inflection point as a company and also as a country. All one needs to do is focus and keep at it.

Excerpts from an interview with Fredun Medhora, Managing Director and CFO, Fredun Pharmaceuticals Ltd.

Rate this article:
5.0

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary25-Apr, 2024

Penny Stocks25-Apr, 2024

Penny Stocks25-Apr, 2024

Mindshare25-Apr, 2024

Mindshare25-Apr, 2024

Knowledge

Fundamental21-Apr, 2024

General21-Apr, 2024

Technical19-Apr, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR